1158P Study of patients’ characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC

Autor: E. Auclin, P. Du Rusquec, V. Albarran, F. Aboubakar, H. Gerber, N. Epaillard, G. Recondo, H. Berthou, E. Fabre-Guillevin, J.C. Laguna Montes, J.B. Blaquier, B.E. Jimenez Munarriz, M. Tagliamento, G. Sacco, J.N. Minatta, N. Girard, M.T. Moran Bueno, R. López Castro, B. Besse, L. Mezquita

Publikováno v: Annals of Oncology, Vol. 33, no.Suppl 7, p. S1078 (2022)

BACKGROUND : In first line (L1) for EGFR-mutated (mEGFR) advanced NSCLC (aNSCLC), osimertinib (osi) has been the preferred option since 2018. First generation anti-EGFR TKI (1G) alone followed by osi, or 1G + anti-angiogenic or 1G + chemotherapy are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d57dfcd33f2ffde58502a8af5661d03c
https://hdl.handle.net/2078.1/268030

1073P Relationship between basal metabolism, nivolumab clearance and survival in metastatic non-small cell lung cancer patients of the ELY study

Autor: A. Puszkiel, P. Boudou Rouquette, J. Arrondeau, M. Wislez, E. Fabre-Guillevin, G. Bianconi, X. Declèves, A. Jouinot, S. De Percin, J. Alexandre, F. Goldwasser, B. Blanchet

Publikováno v: Annals of Oncology. 33:S1044

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a04462cae34818a694c71cd6c6bccab
https://doi.org/10.1016/j.annonc.2022.07.1199

Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer

Autor: J-L Liénard, E Quinaux, E Fabre-Guillevin, P Piedbois, A Jouhaud, G Decoster, M Buyse, null on behalf of the European Association for Research in Oncolo

Publikováno v: Clinical Trials
Clinical Trials, SAGE Publications, 2006, 3, pp.486--492. ⟨10.1177/1740774506070807⟩
Clinical Trials, 2006, 3, pp.486--492. ⟨10.1177/1740774506070807⟩

Purpose To provide empirical evidence on the impact of on-site initiation visits on the following outcomes: patient recruitment, quantity and quality of data submitted to the trial coordinating office, and patients' follow-up time. Patients and metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cc8e82e3a725c80600d44ec8e996454
https://doi.org/10.1177/1740774506070807

[Lung metastasis surgery, yesterday and now]

Autor: F, Le Pimpec Barthes, E, Fabre-Guillevin, C, Foucault, A, Cazes, A, Dujon, M, Riquet

Publikováno v: Revue des maladies respiratoires. 28(9)

Surgical resection of lung metastases may prolong survival as a part of multimodality treatment. Our aim was to review how the indications and practice of this type of surgery have evolved over time.We included in the study all patients who were oper

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::63ba75035dee0e3d1fa80c28d134beed
https://pubmed.ncbi.nlm.nih.gov/22123141

What is the place of clinical variables in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy ?

Autor: Florian Scotté, K. Rideller, M. Berhoune, O. Cojocarasu, Eric Levy, E. Fabre-Guillevin, J. Medioni, J. Ayllon, Eugeniu Banu, Brigitte Bonan

Publikováno v: ASCO Annual Meeting Proceedings
ASCO Annual Meeting Proceedings, 2007, United States. pp.Elec. Proc

18197 Background: Chemotherapy (CT) has shown its effectiveness in symptom control and quality of life improvement in advanced NSCLC patients. The therapeutic strategy and some clinical variables could have a major impact on outcome. Methods: Our ret

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::647a6894fc23a870dfee7a5a8d5dc888
https://hal.archives-ouvertes.fr/hal-00339690